CWG
IBRX icon

Cornerstone Wealth Group’s ImmunityBio IBRX Stock Holding History

Cornerstone Wealth Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
33,704
+796
+2% +$6.03K 0.02% 360
2026
Q1 		$267K Buy
+32,908
New +$225K 0.02% 355

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cornerstone Wealth Group's IBRX Position: Q2 2026 in Review

Cornerstone Wealth Group increased its ImmunityBio (IBRX) stake by 2.4% in Q2 2026, buying an estimated $6.03K and bringing the position to 33,704 shares worth $295K. The position accounts for 0.02% of the portfolio, ranked #360.

Cornerstone Wealth Group first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Cornerstone Wealth Group held 33,704 shares of ImmunityBio worth $295K as of Q2 2026.
  • Cornerstone Wealth Group bought 796 ImmunityBio shares in Q2 2026, an estimated $6.03K.
  • ImmunityBio made up 0.02% of Cornerstone Wealth Group's portfolio in Q2 2026, its #360 holding.
  • Cornerstone Wealth Group first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Cornerstone Wealth Group's 13F filing for Q2 2026, filed 27 Jul 2026.